XML 67 R27.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Collaboration Agreements and Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net | Product Revenue, Net
|  | Years Ended December 31, |
|  | 2019 |  |  | 2018 |
|  | (dollars in thousands) |
Product revenue, net: |  |  |  |  |  |  |  |
API product |  | $ | (36,324 | ) |  | $ | 64,776 |
Drug product |  |  |  |  |  |  |  |
Gross revenue |  |  | 2,803 |  |  |  | — |
Price adjustment |  |  | (936 | ) |  |  | — |
Sales rebates and other discounts |  |  | (167 | ) |  |  | — |
Drug product revenue, net |  |  | 1,700 |  |  |  | — |
Total product revenue, net |  | $ | (34,624 | ) |  | $ | 64,776 |
Japan [Member] |
Summary of Revenue Recognized under Agreement | Amounts recognized as revenue under the Japan Agreement with Astellas were as follows (in thousands):
|  |  |  | Years Ended December 31, |
Agreement |  | Performance Obligation |  | 2019 |  |  | 2018 |  |  | 2017 |
Japan |  | License revenue |  | $ | 11,935 |  |  | $ | 14,323 |  |  | $ | — |
|  | Development revenue |  | $ | 1,222 |  |  | $ | 2,400 |  |  | $ | 1,588 |
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net | The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):
Japan Agreement |  | Cumulative Revenue Through December 31, 2019 |  |  | Deferred Revenue at December 31, 2019 |  |  | Total Consideration Through December 31, 2019 |
License |  | $ | 86,024 |  |  | $ | — |  |  | $ | 86,024 |
Development revenue |  |  | 15,130 |  |  |  | 375 |  |  |  | 15,505 |
Total license and development revenue |  | $ | 101,154 |  |  | $ | 375 |  |  | $ | 101,529 |
Europe [Member] |
Summary of Revenue Recognized under Agreement | Amounts recognized as revenue under the Europe Agreement with Astellas were as follows (in thousands):
|  |  |  | Years Ended December 31, |
Agreement |  | Performance Obligation |  | 2019 |  |  | 2018 |  |  | 2017 |
Europe |  | License revenue |  | $ | 117,470 |  |  | $ | — |  |  | $ | — |
|  | Development revenue |  | $ | 28,172 |  |  | $ | 18,503 |  |  | $ | 18,523 |
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net | The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):
Europe Agreement |  | Cumulative Revenue Through December 31, 2019 |  |  | Deferred Revenue at December 31, 2019 |  |  | Total Consideration Through December 31, 2019 |
License |  | $ | 487,951 |  |  | $ | — |  |  | $ | 487,951 |
Development revenue |  |  | 231,008 |  |  |  | 4,790 |  |  |  | 235,798 |
Total license and development revenue |  | $ | 718,959 |  |  | $ | 4,790 |  | * | $ | 723,749 |
* | Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of December 31, 2019, prepaid expenses and other current assets included a net unbilled contract asset of $125.2 million related to the Europe Agreement, which represents the net of the above-mentioned unbilled contract asset of $130.0 million, and $4.8 million of deferred revenue presented above.
U.S./RoW and China [Member] |
Summary of Revenue Recognized under Agreement | Amounts recognized as revenue under the U.S./RoW and China Agreements with AstraZeneca were as follows (in thousands):
|  |  |  | Years Ended December 31, |
Agreement |  | Performance Obligation |  | 2019 |  |  | 2018 |  |  | 2017 |
U.S. / RoW and China |  | License revenue |  | $ | 47,681 |  |  | $ | 7,946 |  |  | $ | 9,933 |
|  | Development revenue |  |  | 84,629 |  |  |  | 104,970 |  |  |  | 100,928 |
|  | China performance obligation |  | $ | 90 |  |  | $ | — |  |  | $ | — |
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net | The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):
U.S. / RoW and China Agreements |  | Cumulative Revenue Through December 31, 2019 |  |  | Deferred Revenue at December 31, 2019 |  |  | Total Consideration Through December 31, 2019 |
License |  | $ | 341,844 |  |  | $ | — |  |  | $ | 341,844 |
Co-development, information sharing & committee services |  |  | 493,266 |  |  |  | 8,452 |  |  |  | 501,718 |
China performance obligation |  |  | 90 |  |  |  | 140,872 |  |  |  | 140,962 |
Total license and development revenue |  | $ | 835,200 |  |  | $ | 149,324 |  | * | $ | 984,524 |
* | Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of December 31, 2019, long-term deferred revenue included $99.3 million related to the U.S./RoW and China Agreement, which represents the net of $149.3 million of deferred revenue presented above and the above-mentioned $50.0 million unbilled contract asset.

X
- Definition Contract with customer milestone method. + References No definition available. + Details
Name: | fgen_ContractWithCustomerMilestoneMethodTableTextBlock
Namespace Prefix: | fgen_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |